161 related articles for article (PubMed ID: 37408283)
1. Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).
Lee BW; Min K; Hong EG; Ku BJ; Kang JG; Chon S; Lee WY; Park MK; Kim JH; Kim SY; Song K; Yoo SJ
Endocrinol Metab (Seoul); 2023 Jun; 38(3):328-337. PubMed ID: 37408283
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Kim KS; Han KA; Kim TN; Park CY; Park JH; Kim SY; Kim YH; Song KH; Kang ES; Kim CS; Koh G; Kang JG; Kim MK; Han JM; Kim NH; Mok JO; Lee JH; Lim S; Kim SS; Kim TH; Won KC; Lee KY; Cho JH; Han JY; Kim SH; Nah JJ; Song HR; Lee SE; Kim S;
Diabetes Metab; 2023 Jul; 49(4):101440. PubMed ID: 36906135
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
Cho YM; Deerochanawong C; Seekaew S; Suraamornkul S; Benjachareonwong S; Sattanon S; Chamnan P; Sirirak T; Kosachunhanun N; Pratipanawatr T; Suwanwalaikorn S; Lee WJ; Kim S; Choi S; Kang ES; Oh T; Kwon S; Lee MK
Diabetes Obes Metab; 2020 Jan; 22(1):123-127. PubMed ID: 31478335
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Jabbour SA; Hardy E; Sugg J; Parikh S;
Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension.
Moon JS; Park IR; Kim HJ; Chung CH; Won KC; Han KA; Park CY; Won JC; Kim DJ; Koh GP; Kim ES; Yu JM; Hong EG; Lee CB; Yoon KH
Diabetes Metab J; 2023 Nov; 47(6):808-817. PubMed ID: 37750183
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
12. A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).
Kim HJ; Noh JH; Moon MK; Choi SH; Ko SH; Rhee EJ; Hur KY; Jeong IK
J Diabetes Res; 2024; 2024():8915591. PubMed ID: 38223523
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Kwak SH; Hwang YC; Won JC; Bae JC; Kim HJ; Suh S; Lee EY; Lee S; Kim SY; Kim JH
Diabetes Obes Metab; 2020 Feb; 22(2):173-181. PubMed ID: 31502749
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
Yoon SA; Han BG; Kim SG; Han SY; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang YH; Shin SH; Cha DR
Diabetes Obes Metab; 2017 Apr; 19(4):590-598. PubMed ID: 28019072
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.
Han KA; Kim YH; Kim DM; Lee BW; Chon S; Sohn TS; Jeong IK; Hong EG; Son JW; Nah JJ; Song HR; Cho SI; Cho SA; Yoon KH
Diabetes Metab J; 2023 Nov; 47(6):796-807. PubMed ID: 36756676
[TBL] [Abstract][Full Text] [Related]
18. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
19. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Yang SJ; Min KW; Gupta SK; Park JY; Shivane VK; Pitale SU; Agarwal PK; Sosale A; Gandhi P; Dharmalingam M; Mohan V; Mahesh U; Kim DM; Kim YS; Kim JA; Kim PK; Baik SH
Diabetes Obes Metab; 2013 May; 15(5):410-6. PubMed ID: 23170990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
